PMA device
TruSight Oncology Comprehensive
Illumina, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Aug 21, 2024, newest Aug 14, 2026Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
3
Naming "TruSight"
MAUDE reports
0
Brand "TruSight", since 2015
PubMed studies
392
Mentioning "TruSight"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TruSight Oncology Comprehensive
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- TruSight Oncology ComprehensivePMA supplement
P230011-S006 · Decided Aug 14, 2026 · 269 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- TruSight Oncology ComprehensivePMA supplement
P230011-S002 · Decided Jun 26, 2026 · 512 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P230011 · Decided Aug 21, 2024 · 520 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "TruSight", any status and sponsor, newest update first.
National Cancer Institute (NCI)NIH
NCT06090669 · 71 participants (planned) · Start Dec 19, 2023 · Primary completion Oct 30, 2027
Device: TruSight Oncology · For: Inherited Bone Marrow Failure Syndrome; Familial Platelet Disorder With Predisposition to Myeloid Malignancies
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT06904066 · 86 participants (planned) · Start Oct 28, 2026 · Primary completion Apr 30, 2029
Device: TruSight Oncology (TSO) 500 · For: Malignancy, Hematologic; Neoplasms, Hematologic; Neoplasms, Hematopoietic and 8 more
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT07067138 · 175 participants (planned) · Start Feb 23, 2026 · Primary completion Aug 4, 2027
Device: Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT); TruSight(R) Oncology 500 and 1 more · For: Breast Cancer; Breast Carcinoma; Cancer of the Breast and 1 more
Sites: Bethesda, Maryland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TruSight", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TruSight"[tiab]. The summary above synthesizes these.
- Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy.
Mazzarotto F, Tayal U, Buchan RJ, et al. · Circulation · 2020Research Support, Non-U.S. Gov't
- Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
Wei B, Kang J, Kibukawa M, et al. · J Mol Diagn · 2022Research Support, Non-U.S. Gov't
- Clinical Validation of the TruSight Oncology 500 Assay for the Detection and Reporting of Pan-Cancer Biomarkers.
Al-Kateb H, Knight SM, Sivasankaran G, et al. · J Mol Diagn · 2025Validation Study
- Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
Chang HY, Dermawan J, Sharma A, et al. · Mod Pathol · 2024Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- HLA-B leader genotypes in a clinical population.
Balgansuren G, Sprague M, Peterson P, et al. · HLA · 2023Research Support, N.I.H., Extramural
- Molecular Epidemiology in 591 Italian Probands With Nonsyndromic Retinitis Pigmentosa and Usher Syndrome.
Colombo L, Maltese PE, Castori M, et al. · Invest Ophthalmol Vis Sci · 2021Research Support, Non-U.S. Gov't
- Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.
Corti G, Buzo K, Berrino E, et al. · NPJ Precis Oncol · 2024
- Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
de Kock L, Cuillerier A, Gillespie M, et al. · Am J Med Genet A · 2024Research Support, Non-U.S. Gov't
- Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS.
Chao A, Huang HJ, Lin CY, et al. · Endocr Relat Cancer · 2023Research Support, Non-U.S. Gov't
- Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
Hocking AJ, Mortimer LA, Farrall AL, et al. · Lung Cancer · 2024Research Support, Non-U.S. Gov't
- Genomic Insights Into High-Grade Infarct-Associated Bone Sarcomas.
Tvrdik T, Gjeorgjievski SG, Wong P, et al. · Mod Pathol · 2024Research Support, Non-U.S. Gov't
- Multi-gene testing in neurological disorders showed an improved diagnostic yield: data from over 1000 Indian patients.
Ganapathy A, Mishra A, Soni MR, et al. · J Neurol · 2019
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.